Mind Medicine (MindMed) Inc. (MNMD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Vancouver, BC, Canada. The current CEO is Robert Barrow.
MNMD has IPO date of 2016-11-15, 74 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $1.56B.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
